23Indexed trials
mesh condition
Depressive Disorder, Treatment-Resistant
Intelligence
Depressive Disorder, Treatment-Resistant intelligence: 23 indexed trials, 7 recruiting studies, 20 sponsors across 11 countries.
7Recruiting
20Sponsors
11Countries
Leading sponsors
Janssen Research & Development, LLC20 recruiting
Charite University, Berlin, Germany20 recruiting
Massachusetts General Hospital20 recruiting
Jordan F. Karp10 recruiting
King's College London10 recruiting
ReST Therapeutics10 recruiting
Relmada Therapeutics, Inc.10 recruiting
Rupert Lanzenberger10 recruiting
University Health Network, Toronto11 recruiting
University Hospital Freiburg10 recruiting
University Hospital, Tours10 recruiting
University of Calgary10 recruiting
Geographic activity
United States8trials
Germany5trials
United Kingdom4trials
Canada3trials
Italy2trials
Austria2trials
Spain1trials
Greece1trials
France1trials
Australia1trials
Belgium1trials
Leading interventions
Ketamine Hydrochloride2trials
EVT 1011trials
Fluoroethylnormemantine (FENM)1trials
Esketamine 84 mg1trials
Esketamine Nasal Product1trials
Esketamine hydrochloride1trials
Esketamine 56 mg1trials
EMONO1trials
Ketamine hydrochloride1trials
Low Field Magnetic Stimulation (LFMS)1trials
Medi-TBS1trials
DBS of Cg251trials
Methodology note
This entity is derived from structured ClinicalTrials.gov conditions and/or MeSH normalization. Counts reflect the current NeuroRisk indexed corpus and are not guaranteed exhaustive global totals.